British biotechs raised £182 million, showing VCs are continuing to invest in U.K. biotechs despite political uncertainty.
Appetite for biotech IPOs still appears high as Hookipa Pharma filed for a meaty public offering to boost its midstage cancer and infectious disease work.
The funding will support research intended to improve the chances that Inflazome will succeed in the clinic.
Swedish p53 cancer biotech Aprea Therapeutics has nabbed former Agios senior medical director Eyal Attar as its senior vice president and chief medical officer…
The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.
Patients taking GlaxoSmithKline’s anti-BCMA treatment for multiple myeloma had an overall response rate of 60% and median progression-free survival of one year…
The latest setback saw the Novartis-partnered liver disease drug fail to beat placebo in NASH patients, wiping another 50% off Conatus’ stock price.
The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.
NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
Eisai is starting new trials for BAN2401, just 24 hours after dumping phase 3 trials of aducanumab.